We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Summit Therapeutics Plc | LSE:SUMM | London | Ordinary Share | GB00BN40HZ01 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 20.50 | 18.00 | 23.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMSUMM Summit Therapeutics plc ('Summit' or the 'Company') Summit Therapeutics to Report Financial Results for the Second Quarter and Half Year Ended 31 July 2018 on 20 September 2018 Oxford, UK, and Cambridge, MA, US, 14 September 2018 - Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation, will announce its financial results for the second quarter and half year ended 31 July 2018 on 20 September 2018. Summit will host a conference call the same day at 1:00pm BST / 8:00am EDT. Conference call information will be included in the second quarter and half year results press release, and a replay of the call will also be available through the Company's website, https://www.globenewswire.com/Tracker?data=YiC3mqbAGYWY9a91afF2eeuwffRSgLLysMp7aj83EW8l2ROVHYA0kYpux3P97rDPhe4W7XKN-ZmKYLia-klbif2euYu-YhaxgV0TVHq_EQc= www.summitplc.com. About Summit Therapeutics Summit Therapeutics is a leader in antibiotic innovation. Our new mechanism antibiotics are designed to become the new standards of care for the benefit of patients, and create value for payors and healthcare providers. We are currently developing new mechanism antibiotics for C. difficile infection and gonorrhoea and are using our proprietary Discuva Platform to expand our pipeline. For more information, visit www.summitplc.com and follow us on Twitter @summitplc. Contacts Summit Glyn Edwards / Richard Pye (UK office) Tel: 44 (0)1235 443 951 Erik Ostrowski / Michelle Avery (US office) +1 617 225 4455 Cairn Financial Advisers LLP (Nominated Adviser) Tel: +44 (0)20 7213 0880 Liam Murray / Tony Rawlinson N+1 Singer (Joint Broker) Tel: +44 (0)20 7496 3000 Aubrey Powell / Jen Boorer, Corporate Finance Tom Salvesen, Corporate Broking Panmure Gordon (Joint Broker) Tel: +44 (0)20 7886 2500 Freddy Crossley, Corporate Finance James Stearns, Corporate Broking MSL Group (US) Tel: +1 781 684 6557 mailto:summit@mslgroup.com Jon Siegal summit@mslgroup.com --------------------------------- Consilium Strategic Communications (UK) Tel: +44 (0)20 3709 5700 Mary-Jane Elliott / Jessica Hodgson / mailto:summit@consilium-comms.com summit@consilium-comms.com --------------------------------- Lindsey Neville -END-
(END) Dow Jones Newswires
September 14, 2018 07:00 ET (11:00 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year Summit Therapeutics Chart |
1 Month Summit Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions